News & Events
Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need
| Press release
Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025
| Press release
Artios to Announce First Phase 1/2a Data for DNA Polymerase Theta (Pol胃) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO
| Press release
Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)
| Press release
Artios Pharma 天美传媒 Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib (ART0380) into Late-stage Development
| Press release
